NCIt definition : A preparation of autologous peripheral blood T-lymphocytes (PBTL) that have been genetically
modified to express the chimeric antigen receptor (CAR) anti-CD19/CD3 zeta chain fusion
protein coupled to the intracellular signal domain of CD28 antigen, with potential
immunostimulating and antineoplastic activities. Upon administration, autologous PBTL
CD19CAR-28 zeta may stimulate host cytotoxic T lymphocyte (CTL) and antibody responses
against CD19-expressing tumor cells, resulting in tumor cell lysis. CD19 antigen is
a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
CD3 zeta is one of several membrane-bound polypeptides found in the T-cell receptor
(TCR)/CD3 complex and regulates the assembly of complete TCR complexes and their expression
on the cell surface. CD28 is essential for CD4 T-cell proliferation, interleukin-2
production, and T-helper type-2 (Th2) development.;